Skip to main content
. Author manuscript; available in PMC: 2008 Mar 17.
Published in final edited form as: Oncogene. 2007 Jul 16;27(6):831–838. doi: 10.1038/sj.onc.1210681

Figure 5.

Figure 5

Effects of siRNA transfection on the expression of Fo-ATPase d-subunit and docetaxel resistance in DRHEp2. (a) DRHEp2 was transfected with Stealth RNAi specific for Fo-ATPase d-subunit or nonsilencing negative control. Cells were harvested after 24, 48, 72, and 96 hours, and cell lysates were subjected to Western blot analysis using the antibodies indicated (right). (b) After 24 hours, DRHEp2 (●) and DRHEp2 transfected with Stealth RNAi specific for Fo-ATPase d-subunit (▲) or nonsilencing negative control (■) were treated with docetaxel for 72 hours. For each sample, 100% cell survival was set as OD550 of docetaxel-untreated cells. Results are presented as the mean ± standard error of triplicate experiments. *, P < .001 as determined using two-tailed unpaired Student’s t test when cells transfected with Stealth RNAi specific for Fo-ATPase d-subunit and then treated with docetaxel were compared with cells treated with docetaxel alone.